The Food and Drug Administration (FDA) has relaxed certain premarket requirements concerning mental illness or psychiatric issues concerning the pandemic outbreak and with a view to support depression, obsessive-compulsive disorder, anxiety, and insomnia.

FDA states in the guidance, "In the context of the COVID-19 public health emergency, the use of digital health technologies, including software as a medical device or other digital therapeutics solutions, may improve mental health and well-being of patients with psychiatric conditions during periods of shelter-in-place, isolation, and quarantine."